KYTO BIOPHARMA INC Inactive Instrument
Kyto Biopharma Inc Stock Other OTC
Equities
US5015721013
Financial & Commodity Market Operators
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
Financials (USD)
| Sales 2020 | 0.01 | Sales 2021 | - | Capitalization | 18.62M |
|---|---|---|---|---|---|
| Net income 2020 | - | Net income 2021 | - | EV / Sales 2020 | 926,138,940 x |
| Net cash position 2020 | 28.01K | Net cash position 2021 | 8.26M | EV / Sales 2021 | - |
| P/E ratio 2020 |
-17
x | P/E ratio 2021 |
95
x | Employees | - |
| Yield 2020 * |
-
| Yield 2021 |
-
| Free-Float | 53.62% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Paul Russo
CEO | Chief Executive Officer | 81 | 99-03-04 |
| Director of Finance/CFO | 75 | 18-03-14 | |
| Investor Relations Contact | - | 18-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul Russo
CEO | Chief Executive Officer | 81 | 99-03-04 |
Peter Staple
BRD | Director/Board Member | 72 | 21-01-07 |
Jon Saxe
BRD | Director/Board Member | 88 | 21-01-07 |
Kyto Technology and Life Science, Inc. is an investment company focused on creating an exchange-traded fund (ETF)-like vehicle of diversified and thoroughly vetted start-ups thus defining an entirely new non-correlated asset class. The Companyâs portfolio includes AbFero Pharmaceuticals Inc., Achelios Therapeutics, Inc., Altis Biosystems, AmplifiDX, AOA Inc., Astrocyte Pharmaceuticals Inc. and other.
| 1st Jan change | Capi. | |
|---|---|---|
| +3.22% | 76.02B | |
| -5.22% | 58.52B | |
| -7.91% | 38.59B | |
| +5.78% | 35.66B | |
| -24.81% | 11.9B | |
| +6.55% | 9.22B | |
| -30.26% | 7.73B | |
| +12.61% | 7.29B | |
| -5.29% | 7.35B |
